The UK has approved the first GLP-1 weight loss pill, known as Wegovy (semaglutide), for obese adults with a BMI of 30 or above and those overweight with related conditions like high blood pressure. These tablets, to be taken daily, are part of a weight management plan that includes a reduced-calorie diet and increased physical activity.
Patients will start with a 1.5mg dose, gradually increasing to 4mg, 9mg, and 25mg. Individuals currently using a 2.4mg Wegovy injection weekly can switch to the 25mg tablets once daily. The drug, manufactured by Novo Nordisk, should be taken on an empty stomach with water after an eight-hour fasting period, followed by a 30-minute delay before consuming food or drink.
The Medicines and Healthcare products Regulatory Agency (MHRA) authorized the drug based on a study where adults taking 25mg daily lost an average of 17% of their body weight over 64 weeks, compared to 3% with a placebo. Common side effects include gastrointestinal issues like nausea, diarrhea, and vomiting.
Wegovy works by mimicking GLP-1 actions in the body, regulating appetite and reducing cravings. This approval offers a new option for obesity care, providing oral treatment for long-term weight management. With the obesity epidemic in the UK, additional treatment options are crucial to support sustained weight loss.
The launch of oral weight loss medications is expected to have a significant impact on UK patients, with high demand anticipated. Many individuals are showing interest in these pills as a convenient alternative to injections, potentially widening access to effective weight loss solutions for millions across the country. The availability of weight loss pills is likely to attract increasing demand in the upcoming weeks and months.
